Research programme: narcotic dependency therapeutics - Pfizer

Drug Profile

Research programme: narcotic dependency therapeutics - Pfizer

Alternative Names: CJ 15208

Latest Information Update: 05 Sep 2006

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Drug abuse

Most Recent Events

  • 05 Sep 2006 Discontinued - Preclinical for Drug abuse (unspecified route)
  • 08 Apr 2003 Preclinical trials in Drug abuse (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top